Cargando…
Optimized Treatment Schedules for Chronic Myeloid Leukemia
Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients. Recent studies have shown that resistance mutations tha...
Autores principales: | He, Qie, Zhu, Junfeng, Dingli, David, Foo, Jasmine, Leder, Kevin Zox |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072565/ https://www.ncbi.nlm.nih.gov/pubmed/27764087 http://dx.doi.org/10.1371/journal.pcbi.1005129 |
Ejemplares similares
-
Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia
por: Leder, Kevin, et al.
Publicado: (2011) -
What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature
por: Jamison, Caroline, et al.
Publicado: (2016) -
Optimizing Outcomes Through Pharmaceutical Advances in the Treatment of Chronic Myeloid Leukemia
por: Frame, David, et al.
Publicado: (2007) -
Introduction: Optimizing Outcomes Through Pharmaceutical Advances in the Treatment of Chronic Myeloid Leukemia
por: Frame, David
Publicado: (2007) -
Eradication of Chronic Myeloid Leukemia Stem Cells: A Novel Mathematical Model Predicts No Therapeutic Benefit of Adding G-CSF to Imatinib
por: Foo, Jasmine, et al.
Publicado: (2009)